A new study involving octreotide was published on October 27, 2026. The publication, titled "Octreotide-modified pH-responsive nanocomposites for ultrasound imaging-guided chemo-photothermal therapy of prostate cancer," appeared in the journal Nanoscale. The work is listed under PubMed ID 42944769. This entry reflects a publication event only, noting the title, journal, and publication date as recorded. No findings, outcomes, or results from the study are included in this report. Octreotide remains an approved compound, and this publication represents a new addition to the research literature referencing it. Readers interested in the broader context of octreotide, including its approved uses and regulatory status, can consult the compound overview for additional background. This brief does not characterize the nature of the results, efficacy, or safety implications associated with the nanocomposite formulation described in the study. Further details are available directly through the journal listing and the associated PubMed record linked in the sources.
Octreotide-Modified Nanocomposites Study Published in Nanoscale
See the full octreotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42944769/